1-5 of 5
Ramy Ibrahim, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Design Of a Phase 1/2 Study Of Moxetumomab Pasudotox In Adult Patients With Relapsed and/Or Refractory Acute Lymphoblastic Leukemia (ALL)

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Trishna Goswami, MD, Fujun Wang, PhD, Ramy Ibrahim, MD
Journal: Blood
Blood (2013) 122 (21): 5021.
https://doi.org/10.1182/blood.V122.21.5021.5021
Published: 2013
Journal Articles

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

Andres Forero-Torres, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Celeste M. Bello, MD, Thomas J. Kipps, MD, PhD, Fritz Offner, MD, Gregor Verhoef, Massimo Federico, MD, Stephanie A. Gregory, MD, Anne Sonet, MD, Sarit Assouline, MD, Jaime Pérez de Oteyza, Jose Francisco Tomas, MD, Antonio Cuneo, MD, Nairouz Elgeioushi, MPH, Trishna Goswami, MD, Ramy Ibrahim, MD, Ronald Herbst, PhD, Bruce D. Cheson, M.D.
Journal: Blood
Blood (2013) 122 (21): 1810.
https://doi.org/10.1182/blood.V122.21.1810.1810
Published: 2013
Journal Articles

MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

Andres Forero, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Celeste M. Bello, MD, Thomas J Kipps, MD, PhD, Fritz Offner, Gregor Verhoef, Massimo Federico, MD, Stephanie A. Gregory, MD, Anne Sonet, MD, Sarit Assouline, Jaime Pérez de Oteyza, Jose Francisco Tomas, Antonio Cuneo, MD, Weiya Zhang, Trishna Goswami, MD, Ramy Ibrahim, MD, Zhenling Yao, Ronald Herbst, PhD, Bruce D. Cheson, MD
Journal: Blood
Blood (2012) 120 (21): 3677.
https://doi.org/10.1182/blood.V120.21.3677.3677
Published: 2012
Journal Articles

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

Robert J. Kreitman, MD, Evgeny Arons, PhD, Sapolsky Jeffrey, Laura Roth, Hong Zhou, BS, Maryalice Stetler-Stevenson, MD, PhD, Wyndham H. Wilson, MD, PhD, Mark Raffeld, MD, David J. P. FitzGerald, PhD, Ji Fei, PhD, Ramy Ibrahim, MD, Ira Pastan, MD
Journal: Blood
Blood (2012) 120 (21): 2896.
https://doi.org/10.1182/blood.V120.21.2896.2896
Published: 2012
Journal Articles

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Alan S Wayne, MD, Deepa Bhojwani, MD, Lewis B. Silverman, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PhD, Nirali N Shah, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Manuela Buzoianu, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Ramy Ibrahim, MD, Ira Pastan, MD
Journal: Blood
Blood (2011) 118 (21): 248.
https://doi.org/10.1182/blood.V118.21.248.248
Published: 2011